Association of GSTM1 Polymorphism and Redox Potential with Idiopathic Male Infertility
by
, , , ,
Anastasios Potiris
1,†,
Anastasia Voitse
2,†,
Despoina Mavrogianni
2,*,
Nikolaos Machairiotis
1,
Eirini Drakaki
2,
Myrto Papamentzelopoulou
2,
Theodoros Karampitsakos
1,
Athanasios Zikopoulos
3,
Evangelini Evgeni
4,
Peter Drakakis
1,2 and
Sofoklis Stavros
1 1
Third Department of Obstetrics and Gynecology, University General Hospital “ATTIKON”, Medical School, National and Kapodistrian University of Athens, 124 62 Athens, Greece
2
First Department of Obstetrics and Gynecology, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece
3
Department of Obstetrics and Gynecology, Royal Cornwall Hospital, Treliske TR1 3LQ, UK
4
Cryogonia Cryopreservation Bank, 115 26 Athens, Greece
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2023, 12(21), 6775; https://doi.org/10.3390/jcm12216775
Submission received: 5 October 2023
/
Revised: 22 October 2023
/
Accepted: 25 October 2023
/
Published: 26 October 2023
(This article belongs to the Special Issue Gynecologic and Obstetric Pathologies: From Birth to Menopause)
Abstract
:Background: The aim of this case–control study is to investigate possible associations between GSTM1 polymorphism and redox potential with sperm parameters. Methods: The study group consisted of sperm samples from 51 infertile men according to the WHO guidelines. The control group included 39 samples from men with normal seminal parameters. DNA was extracted and genotyped for the detection of the GSTM1 polymorphism. An evaluation of the static redox potential (sORP) using the MiOXSYSTM system was conducted. Results: The frequency of the GSTM1-null genotype was higher in infertile male individuals (60.78%) than in the controls (41.03%) and was associated with a 2.228-fold increased risk for male infertility. Fertile controls carrying the GSTM1-null genotype presented a lower percentage of typical sperm morphology and lower slow progressive motility. An excess of redox potential was observed in infertile males compared to fertile ones. In the control group higher sORP values had a positive correlation with immotility percentage and a negative correlation regarding total motility. In the study group sORP values had a negative correlation with total count, concentration, and slow progressive motility. Conclusions: The present study highlights that GSTM1 polymorphism and redox potential affect both fertile and in fertile males. Moreover, redox potential levels could be used as an additional indicator along with the routine semen analysis for a comprehensive screening between infertile and fertile men.
1. Introduction
Despite advances in male reproductive health, idiopathic male infertility remains a challenging condition in diagnosis and treatment. Increasing data suggest that oxidative stress plays a major role in the pathophysiology of male infertility, with 30% to 80% of infertile men having elevated levels of free radicals in sperm [1]. Therefore, a comprehensive assessment of male reproductive capacity should include an assessment of sperm oxidative stress. Human semen contains several antioxidant systems to remove oxygen free radicals and prevent oxidative tissue damage. They are classified as enzymatic and non-enzymatic antioxidants [2]. The formation of the enzymatic antioxidant system, the elements of which vary between organisms, is a crucial breakthrough in spermatogenesis to ensure the protection of sperm against oxidative stress [3]. Under normal conditions, reactive oxygen species (ROS) are neutralized by enzymes such as peroxide dismutase, catalase, glutathione peroxidase, and glutathione transferase [4].
Glutathione S-transferases (GSTs) comprise a superfamily of ubiquitously expressed multifunctional enzymes that play a pivotal role in protecting cells against oxidative stress. Among them, the GSTM1 gene, encoding the glutathione S-transferase Mu-1, is mutated and is devoid of any specific enzymatic activity (GSTM1-null genotype). Interestingly, half of the Caucasian population carry the null genotype. Therefore, GSTM1 gene deletion might be correlated with an increased susceptibility to diseases associated with oxidative stress. There are also studies reporting that GSTM1 might be a critical isozyme in the detoxification of oxidative stress products [2,5,6].
An association has been demonstrated between GSTM1 polymorphism, markers of oxidative stress, and damage in spermatozoa and seminal plasma in subjects with idiopathic male infertility. Infertile individuals with the GSTM1-null genotype are more susceptible to oxidative stress than GSTM1-positive infertile males. Furthermore, the GSTM1-null genotype has been associated with higher ROS, protein carbonyl, and malondialdehyde (MDA) levels [2].
The aim of the present study is to investigate the effect of GSTM1 polymorphism and static redox potential (sORP) to the basic seminal parameters of fertile and infertile men. Furthermore, our study’s aim is to examine whether testing for GSTM1 polymorphism could be a potential biomarker in male infertility investigation.
2. Materials and Methods
2.1. Sample Collection
The case–control study was conducted at “Alexandra” University Hospital in collaboration with the sperm cryopreservation bank “Cryogonia” and a written informed consent was obtained from all the involved patients. The study included 90 Caucasian males divided into two groups, namely the study group and the control group. The study group consisted of semen samples from 51 men identified as infertile according to the WHO 2010 guidelines (study group). Control group consisted of 39 fertile men with normal seminal parameters according to the WHO 2010 guidelines, and at least one successful pregnancy with their partner without assisted reproductive technologies. Exclusion criteria for both groups include evidence of any other fertility-related disease, such as prostate cancer, cryptorchidism, varicocele, diabetes, seminal infections, or karyotype abnormalities. Moreover, individuals with obesity (body mass index greater than 30 kg/m2), systematic alcohol consumption, or active nicotine abuse were also excluded. Each subject donated 1 mL (patient cohort) or 0.5 mL (donor cohort) of ejaculated semen obtained by masturbation after a minimum of 4 days of abstinence.
2.2. Semen Analysis
Each sample was subjected to conventional semen analysis according to the recommendations, semen evaluation protocols, and standards of the World Health Organization (WHO). More specifically, seminal volume, sperm concentration, motility, and morphology were analyzed 30 min after liquefaction.
2.3. DNA Extraction and Detection of GSTM1 Polymorphism
DNA was isolated from all sperm samples using a commercial PureLink™ Genomic DNA Mini Kit (Thermo Fisher Scientific, Waltham, MA, USA). DNA quantification was performed via spectrophotometer, and DNA integrity was verified by agarose electrophoresis. Polymerase Chain Reaction was performed to detect GSTM1 polymorphism. A Taq DNA polymerase kit (New England Biolabs, Ipswich, MA USA) was used, and the primers were the following: GSTM1F 5′-GAACTCCCTGAAAAGCTAAAGC-3′ and GSTM1R 5′-GTTGGGCTCAAATATACGGTGG-3′ [7]. The conditions of the PCR were as follows: 94 °C for 10 min, 94 °C for 1 min, 58 °C for 1 min, 72 °C for 1 min. This was repeated for 35 cycles, with a final elongation step at 72 °C for 10 min. Subsequently, the PCR products were electrophoresed on 2% agarose gel and visualized under UV light. A single band at 219 bp corresponded to the presence of the GSTM1.
2.4. Evaluation of Oxidative Stress Using the MiOXSYSTM System
The MiOXSYSTM system (GryNumber Health Group, Vilnius, Lithuania) provides an evaluation of the static redox potential (sORP), which represents an integrated measure of the balance between total levels of oxidants and antioxidants in a biological system or sample, such as human semen. The MiOXSYSTM system requires a small semen volume (30 μL) and produces results in less than 5 minutes. The measurement of sORP offers the andrology and embryology laboratory an efficient tool for the measurement of oxidative stress. The assay provides the possibility to directly assess the oxidative potential in semen samples in contrast to oxidative stress markers such as ROS, TAC or MDA. Its advantages compared to other methods of oxidative stress evaluation include short duration, technical simplicity, as well as small sample volume required for the measurement.
2.5. Statistical Analysis
The χ2-test was performed to compare GSTM1-null genotype frequencies between groups. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between variant genotype and group. T-test for two independent samples (or Mann–Whitney U, if this was deemed necessary) was performed to compare variant genotype and conventional semen parameters by group. Pearson’s correlation coefficient was used to determine the effect of sORP in semen parameters. The data were analyzed using the Statistical Package for Social Sciences software version 20.0 (SPSS Inc., Chicago, IL, USA), and p < 0.05 was considered statistically significant.
3. Results
3.1. General Characteristics and Conventional Semen Parameters in Study and Control Groups
The present case–control study included 90 Caucasian males, of whom 51 (56.67%) and 39 (43.33%) were included in the study and control groups, respectively. The mean age of the infertile and fertile individuals was 38.67 ± 6.46 years and 39.21 ± 6.64 years, respectively. Both groups were age matched, and there was no significant difference in the age distribution between the control and study group. There was no difference in BMI and lifestyle factors between both groups.
Conventional semen parameters, including sperm motility, concentration, and morphology for both groups are reported in Table 1. Sperm concentration was lower in the study group compared to controls, a finding with statistical significance (26.78 × 106/mL vs. 90.92 × 106/mL, p < 0.001). Likewise, total sperm count was statistically significantly restricted in infertile men compared to in those who were fertile (81.49 × 106 vs. 275.89 × 106, p < 0.001). Moreover, infertile subjects presented decreased total sperm motility compared to the controls, an observation that reached statistical significance (47.80% vs. 55.62%, p < 0.001). Accordingly, the immotile sperm percentage was statistically significantly higher in the study group than in the controls (48.86% vs. 21.56%, p < 0.001). In addition, sperm morphology was found to be diminished in infertile men compared to fertile ones (2.82% vs. 8.41%, p < 0.001).
3.2. GSTM1-Null Genotype Frequencies and Association with Conventional Semen Parameters
The genotype distribution of GSTM1 polymorphism in patients with infertility and in the controls is presented in Table 2. The frequency of the GSTM1-null genotype was higher in infertile male individuals (31/51; 60.78%) than in the controls (16/39; 41.03%), with an OR of 2.228, but it was not statistically significant. Furthermore, the presence or absence of GSTM1 polymorphism was studied in relation to sperm concentration, motility, and morphology parameters. This analysis aimed to investigate whether the absence of GSTM1 gene affects conventional semen parameters, such as morphology and motility, in fertile and infertile men. For the control group (Table 3), the presence of the GSTM1-null genotype was associated with a higher pH (7.600 ± 0.110 vs. 7.400 ± 0.100, p = 0.033), lower percentage of slow progressive motility (39.94 ± 9.81 vs. 45.91 ± 9.01, p = 0.043) and lower percentage of morphologically typical spermatozoa (7.19 ± 2.83 vs. 9.26 ± 2.94, p = 0.020). Moreover, the percentage of immotile spermatozoa was higher in GSTM1-null genotype carriers (26.31 ± 13.45 vs. 18.26 ± 7.62, p = 0.053), but it was not statistically significant. Interestingly, there were no statistically significant differences between the GSTM1-null genotype and conventional semen parameters in infertile male individuals (Table 4).
3.3. Association of Static Oxidation-Reduction Potential (sORP) with Conventional Semen Parameters
Τhe measurement of oxidative stress using the MiOXSYS™ system was performed on 52 individuals in total, with an average value of 4.58 ± 7.72 mV. More specifically, in the control group, the measurement of oxidative stress was performed in nine individuals with an average value of 0.91 ± 0.8 mV, while in the infertile group, the measurement of oxidative stress was performed in 43 individuals with an average value of 5.35 ± 8.29 mV. The two groups differed significantly (p = 0.0013), indicating that an excess of ROS was detected in infertile men compared to fertile ones. Figure 1 presents the averages and distribution of Static Oxidation-reduction Potential data in fertile and infertile men.
Regarding the association of oxidation-reduction potential with conventional semen parameters in infertile individuals (Table 5), sperm concentration and total sperm count had a statistically significant negative correlation with increased sORP values. Likewise, slow progressive motility was negatively correlated with oxidation-reduction potential. On the other hand, in the control group (Table 6), there was a negative correlation between the increase in sORP values and total motility percentage. Additionally, there was a positive correlation between increased sORP and immotile spermatozoa. All the above-mentioned correlations indicate that when seminal plasma sORP increases, semen count and motility parameters decline in infertile men and only motility parameters decline in fertile men.
Interestingly, a negative correlation was found when analyzing the relationship between sORP values in the study group and viscosity of the seminal fluid (Table 7).
4. Discussion
Genetic variants in GST genes may lead to detoxification system imbalance, thereby increasing susceptibility to oxidative stress damage and increased risk for male infertility [8,9]. In particular, several epidemiological studies have shown that the GSTM1-null genotype, which results in total enzyme deficiency, is associated with increased susceptibility to oxidative-stress-related diseases. The possible relationship of GSTM1 gene deficiency with male infertility has been studied extensively, but the results of the studies vary between different populations [10].
The present case–control study focused on the potential impact of the GSTM1 polymorphism and redox potential on the risk for idiopathic male infertility. Our results demonstrated that the GSTM1-null genotype was present at a higher frequency in infertile men than in the fertile control group, with a 2.22-fold increase for the risk of male infertility. Thus, an increased risk of the GSTM1 polymorphism for developing male factor infertility is supported.
Our results are in agreement with several studies that reveal GSTM1-null genotype as a potential risk factor for male idiopathic infertility by affecting semen quality [11,12,13,14,15,16]. Numerous population studies have suggested a negative effect of the GSTM1-null genotype on male infertility, with patients carrying the GSTM1-null genotype having a lower sperm concentration and sperm count. Fertile males with the GSTM1-null genotype had a lower sperm concentration but normal sperm count [17,18]. More importantly, a similar relative risk for male factor infertility was observed in patients with the GSTM1-null genotype. The same study showed that the combination of deletion genotypes of GST genes pose an even higher risk for infertility [19].
Impaired semen quality is reported in infertile men regarding sperm concentration, count, motility, and morphology compared to fertile ones. In our study, fertile individuals carrying the GSTM1-null genotype were found to have a lower percentage of typical spermatozoa regarding morphology and lower slow progressive motility, highlighting the negative effect of the presence of GSTM1 polymorphism in conventional semen parameters in fertile males. Notably, Aydemir et al. showed that lower sperm concentrations and higher levels of oxidative stress and damage markers are presented in infertile males with the GSTM1-null genotype compared to those with the GSTM1-positive genotype. However, no significant difference in genotype distribution for the GSTM1 variant between idiopathic infertile subjects and fertile ones was observed [2]. Another study also demonstrated lower sperm concentration and motility in infertile men carrying the GSTM1-null genotype compared to fertile ones with the GSTM1-positive genotype. Similarly, the frequency of the GSTM1-null genotype was significantly higher in infertile individuals than in fertile ones. Their findings are consistent with our research results [20].
Moreover, an increased risk for male infertility of GSTM1-null genotype was revealed in a previous meta-analysis. Interestingly, an even higher risk was reported upon a subgroup analysis of Caucasians [21]. Similarly, a subsequent meta-analysis concluded that the GSTM1-null polymorphism contributes to a significant increased risk for male infertility. Therein, significant associations were also observed in subgroups of Caucasian populations but not in Asian ones [22].
On the contrary, in a meta-analysis conducted by Economopoulos et al., the GSTM1-null genotype was not statistically associated with male infertility, underscoring the need for the accumulation of data regarding variants of GST genes [23]. However, in a recent study, researchers proposed the GSTM1-null genotype as a potential genetic risk factor for male infertility, interfering with certain oxidative stress markers (i.e., total antioxidant capacity and nitric oxide) in infertile men [24].
With regard to oxidative stress variations, our results demonstrated an excess of oxidation-reduction potential in infertile men compared to fertile ones. Notably, poor semen quality, including low sperm concentration and count, higher percentage of slow progressive motility and immature forms, was reported upon redox potential elevation. Surprisingly, increases in sOPR had a negative impact on the semen motility characteristics of fertile males.
The measure of sORP is considered to be a better indicator of semen quality, providing reliable results for oxidative stress. Agarwal et al. standardized the sORP test in semen using the MiOXSYS System and reported that higher sORP levels were associated with poor sperm parameters, deteriorating the fertility status of subjects. Negative correlations emerged for conventional semen parameters, including concentration, total sperm count, motility, and morphology, indicating that oxidative stress impairs these parameters. The authors proposed testing sORP as an objective and accurate method, which in conjunction to routine semen analysis can reliably differentiate fertile from infertile men [25,26]. However, certain limitations should be taken into consideration regarding the difficulty to assess highly viscous semen using the MiOXSYS system, or conventional semen parameters, such as sperm morphology.
5. Conclusions
In conclusion, our study showed that the GSTM1-null genotype does not significantly affect the semen parameters of the infertile group. On the other hand, the existence of the GSTM1-null genotype in the control group was associated with lower slow progressive motility and less typical spermatozoa. Regarding sORP values, we found a negative correlation with total count, concentration, and slow progressive motility in the infertile group. In the fertile control group, there was a positive correlation with immotility percentage and a negative correlation in total motility. Ultimately, the importance of our results lies in the confirmation that the GSTM1-null genotype and sORP values affect both fertile and infertile males in different ways. Further studies are needed to evaluate the combined or independent use of GSTM1 genotyping as a potential biomarker for male infertility assessment. In addition, redox potential is considered to be a useful indicator of semen quality, distinguishing infertile from fertile males by their sORP values. Accordingly, genetic testing along with an oxidative stress test may contribute to the identification of those infertile patients with increased risk for abnormal semen parameters.
Author Contributions
Conceptualization A.V. and S.S.; methodology, D.M. and E.E.; validation, D.M. and A.Z.; formal analysis, M.P.; data curation, E.D.; writing—original draft preparation, A.P. and A.V.; writing—review and editing, N.M. and T.K.; visualization, A.P.; supervision, E.E. and P.D.; project administration, S.S. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The present study was conducted according to the Declaration of Helsinki for Medical Research involving Human Subjects and approved by the “CRYOGONIA Cryopreservation Bank” Ethics Committee on 11/06/2019 (protocol number 01/11-06-2019).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
Not applicable.
Acknowledgments
We would like to acknowledge the contribution of all recruited patients in the present study.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Alkan, I.; Simsek, F.; Haklar, G.; Kervancioglu, E.; Ozveri, H.; Yalcin, S.; Akdas, A. Reactive oxygen species production by the spermatozoa of patients with idiopathic infertility: Relationship to seminal plasma antioxidants. J. Urol. 1997, 157, 140–143. [Google Scholar] [CrossRef]
- Aydemir, B.; Onaran, I.; Kiziler, A.R.; Alici, B.; Akyolcu, M.C. Increased oxidative damage of sperm and seminal plasma in men with idiopathic infertility is higher in patients with glutathione S-transferase Mu-1 null genotype. Asian J. Androl. 2007, 9, 108–115. [Google Scholar] [CrossRef]
- O’Flaherty, C. Peroxiredoxins: Hidden players in the antioxidant defence of human spermatozoa. Basic. Clin. Androl. 2014, 24, 4. [Google Scholar] [CrossRef]
- Ji, G.; Gu, A.; Wang, Y.; Huang, C.; Hu, F.; Zhou, Y.; Song, L.; Wang, X. Genetic variants in antioxidant genes are associated with sperm DNA damage and risk of male infertility in a Chinese population. Free Radic. Biol. Med. 2012, 52, 775–780. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.S.; Chang, L.S.; Chen, H.W.; Wei, Y.H. Polymorphisms of glutathione S-transferase M1 and male infertility in Taiwanese patients with varicocele. Hum. Reprod. 2002, 17, 718–725. [Google Scholar] [CrossRef] [PubMed]
- Quinones, L.A.; Irarrazabal, C.E.; Rojas, C.R.; Orellana, C.E.; Acevedo, C.; Huidobro, C.; Varela, N.E.; Caceres, D.D. Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: An exploratory genotype-environment interaction study. Asian J. Androl. 2006, 8, 349–355. [Google Scholar] [CrossRef]
- Salehi, Z.; Gholizadeh, L.; Vaziri, H.; Madani, A.H. Analysis of GSTM1, GSTT1, and CYP1A1 in idiopathic male infertility. Reprod. Sci. 2012, 19, 81–85. [Google Scholar] [CrossRef]
- Wu, W.; Lu, J.; Tang, Q.; Zhang, S.; Yuan, B.; Li, J.; Di, W.; Sun, H.; Lu, C.; Xia, Y.; et al. GSTM1 and GSTT1 null polymorphisms and male infertility risk: An updated meta-analysis encompassing 6934 subjects. Sci. Rep. 2013, 3, 2258. [Google Scholar] [CrossRef]
- Turner, T.T.; Lysiak, J.J. Oxidative stress: A common factor in testicular dysfunction. J. Androl. 2008, 29, 488–498. [Google Scholar] [CrossRef]
- Olshan, A.F.; Luben, T.J.; Hanley, N.M.; Perreault, S.D.; Chan, R.L.; Herring, A.H.; Basta, P.V.; DeMarini, D.M. Preliminary examination of polymorphisms of GSTM1, GSTT1, and GSTZ1 in relation to semen quality. Mutat. Res. 2010, 688, 41–46. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; He, J.; Zhao, Y.; Wu, Q.; Zou, T.; Sun, J.; Zhu, H.; Wang, X.; Sun, F.; Xing, J.; et al. Effect of glutathione S-transferase gene polymorphisms on semen quality in patients with idiopathic male infertility. J. Int. Med. Res. 2021, 49, 3000605211061045. [Google Scholar] [CrossRef] [PubMed]
- Kolesnikova, L.I.; Kurashova, N.A.; Bairova, T.A.; Dolgikh, M.I.; Ershova, O.A.; Dashiev, B.G.; Korytov, L.I.; Koroleva, N.V. Role of Glutathione-S-Transferase Family Genes in Male Infertility. Bull. Exp. Biol. Med. 2017, 163, 643–645. [Google Scholar] [CrossRef] [PubMed]
- Xu, X.B.; Liu, S.R.; Ying, H.Q. Null genotype of GSTM1 and GSTT1 may contribute to susceptibility to male infertility with impaired spermatogenesis in Chinese population. Biomarkers 2013, 18, 151–154. [Google Scholar] [CrossRef]
- Dhillon, V.S.; Shahid, M.; Husain, S.A. Associations of MTHFR DNMT3b 4977 bp deletion in mtDNA and GSTM1 deletion, and aberrant CpG island hypermethylation of GSTM1 in non-obstructive infertility in Indian men. Mol. Hum. Reprod. 2007, 13, 213–222. [Google Scholar] [CrossRef] [PubMed]
- Aydos, S.E.; Taspinar, M.; Sunguroglu, A.; Aydos, K. Association of CYP1A1 and glutathione S-transferase polymorphisms with male factor infertility. Fertil. Steril. 2009, 92, 541–547. [Google Scholar] [CrossRef] [PubMed]
- Finotti, A.C.; Costa, E.S.R.C.; Bordin, B.M.; Silva, C.T.; Moura, K.K. Glutathione S-transferase M1 and T1 polymorphism in men with idiopathic infertility. Genet. Mol. Res. 2009, 8, 1093–1098. [Google Scholar] [CrossRef] [PubMed]
- Roshdy, O.H.; Hussein, T.M.; Zakaria, N.H.; Sabry, A.A. Glutathione S-transferase Mu-1 gene polymorphism in Egyptian patients with idiopathic male infertility. Andrologia 2015, 47, 587–593. [Google Scholar] [CrossRef] [PubMed]
- Xiong, D.K.; Chen, H.H.; Ding, X.P.; Zhang, S.H.; Zhang, J.H. Association of polymorphisms in glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) with idiopathic azoospermia or oligospermia in Sichuan, China. Asian J. Androl. 2015, 17, 481–486. [Google Scholar] [CrossRef]
- Safarinejad, M.R.; Shafiei, N.; Safarinejad, S. The association of glutathione-S-transferase gene polymorphisms (GSTM1, GSTT1, GSTP1) with idiopathic male infertility. J. Hum. Genet. 2010, 55, 565–570. [Google Scholar] [CrossRef]
- Tirumala Vani, G.; Mukesh, N.; Siva Prasad, B.; Rama Devi, P.; Hema Prasad, M.; Usha Rani, P.; Pardhanandana Reddy, P. Role of glutathione S-transferase Mu-1 (GSTM1) polymorphism in oligospermic infertile males. Andrologia 2010, 42, 213–217. [Google Scholar] [CrossRef]
- Chengyong, W.; Man, Y.; Mei, L.; Liping, L.; Xuezhen, W. GSTM1 null genotype contributes to increased risk of male infertility: A meta-analysis. J. Assist. Reprod. Genet. 2012, 29, 837–845. [Google Scholar] [CrossRef] [PubMed]
- Song, X.; Zhao, Y.; Cai, Q.; Zhang, Y.; Niu, Y. Association of the Glutathione S-transferases M1 and T1 polymorphism with male infertility: A meta-analysis. J. Assist. Reprod. Genet. 2013, 30, 131–141. [Google Scholar] [CrossRef]
- Economopoulos, K.P.; Sergentanis, T.N.; Choussein, S. Glutathione-S-transferase gene polymorphisms (GSTM1, GSTT1, GSTP1) and idiopathic male infertility: Novel perspectives versus facts. J. Hum. Genet. 2010, 55, 557–558. [Google Scholar] [CrossRef] [PubMed]
- Barati, E.; Karimian, M.; Nikzad, H. Oxidative stress markers in seminal plasma of idiopathic infertile men may be associated with glutathione S-transferase M1 and T1 null genotypes. Andrologia 2020, 52, e13703. [Google Scholar] [CrossRef] [PubMed]
- Agarwal, A.; Roychoudhury, S.; Sharma, R.; Gupta, S.; Majzoub, A.; Sabanegh, E. Diagnostic application of oxidation-reduction potential assay for measurement of oxidative stress: Clinical utility in male factor infertility. Reprod. Biomed. Online 2017, 34, 48–57. [Google Scholar] [CrossRef]
- Agarwal, A.; Bui, A.D. Oxidation-reduction potential as a new marker for oxidative stress: Correlation to male infertility. Investig. Clin. Urol. 2017, 58, 385–399. [Google Scholar] [CrossRef]
Figure 1.
Boxplot presenting Static Oxidation-reduction Potential (sORP) data in study and control groups.
Figure 1.
Boxplot presenting Static Oxidation-reduction Potential (sORP) data in study and control groups.
Table 1.
Comparison of conventional semen parameters in control (n = 39) and study (n = 51) groups.
| Semen Parameters | N0 | Control Group | N1 | Study Group | p-Value |
|---|---|---|---|---|---|
| pH | 9 | 7.53 ± 0.14 | 45 | 7.62 ± 0.21 | 0.240 |
| Days of Abstinence | 39 | 4.10 ± 1.33 | 51 | 3.88 ± 2.20 | 0.585 |
| Semen Volume (mL) | 39 | 2.94 ± 1.16 | 51 | 3.07 ± 1.77 | 0.386 |
| Sperm Concentration (106/mL) | 39 | 90.92 ± 50.40 | 51 | 26.78 ± 29.04 | 0.000 |
| Total Sperm Count (106) | 39 | 275.89 ± 208.42 | 51 | 81.49 ± 101.35 | 0.000 |
| Total Motility (%) | 39 | 55.62 ± 6.50 | 51 | 47.80 ± 12.25 | 0.000 |
| Rapid Progressive Motility (%) | 39 | 2.15 ± 5.22 | 51 | 7.35 ± 9.08 | 0.001 |
| Slow Progressive Motility (%) | 39 | 43.46 ± 9.69 | 51 | 20.71 ± 8.18 | 0.000 |
| Non-progressive Motility (%) | 39 | 32.67 ± 9.46 | 51 | 22.88 ± 14.24 | 0.000 |
| Immotility (%) | 39 | 21.56 ± 11.00 | 51 | 48.86 ± 14.67 | 0.000 |
| Typical Morphology (%) | 39 | 8.41 ± 3.04 | 51 | 2.82 ± 2.33 | 0.000 |
| Head Abnormalities (%) | 1 | 94 | 21 | 98.52 ± 0.75 | 0.000 |
| Midpiece Abnormalities (%) | 1 | 18 | 21 | 28.52 ± 7.80 | 0.202 |
| Tail Abnormalities (%) | 1 | 10 | 21 | 14.57 ± 9.85 | 0.655 |
| Immature Forms (%) | 1 | 0 | 21 | 6.67 ± 3.28 | 0.061 |
| Viscosity (cps) | |||||
| normal | 5 (12.8%) | 12 (23.5%) | |||
| abnormal | 34 (87.2%) | 39 (76.5%) | 0.198 | ||
| Liquefaction | |||||
| normal | 3 (7.7%) | 2 (3.9%) | |||
| abnormal | 36 (92.3%) | 49 (96.1%) | 0.439 |
Values are mean ± SD or number (column percentage). t-test independent sample or Chi-square test was used.
Table 2.
Frequencies of GSTM1-null genotype in control (n = 39) and study (n = 51) groups.
| Group | Risk Estimate | |||||
|---|---|---|---|---|---|---|
| Control | Study | OR | 95% CI for OR | p-Value | ||
| GSTM1 | no | 23 (59.0%) | 20 (39.2%) | 2.228 | [0.952 5.215] | 0.063 |
| yes | 16 (41.0%) | 31 (60.8%) | ||||
Pearson’s Chi-square test was used.
Table 3.
Association of GSTM1-null genotype with conventional semen parameters (control group).
| Semen Parameters | N0 | GSTM1 (No) | N1 | GSTM1 (Yes) | p-Value |
|---|---|---|---|---|---|
| pH | 3 | 7.400 ± 0.100 | 6 | 7.600 ± 0.110 | 0.033 |
| Days of Abstinence | 23 | 4.304 ± 1.636 | 16 | 3.813 ± 0.655 | 0.420 |
| Semen Volume (mL) | 23 | 2.743 ± 1.158 | 16 | 5.206 ± 8.027 | 0.138 |
| Sperm Concentration (106/mL) | 23 | 95.39 ± 52.63 | 16 | 84.50 ± 47.92 | 0.568 |
| Total Sperm Count (106) | 23 | 265.70 ± 202.13 | 16 | 290.54 ± 223.02 | 0.808 |
| Total Motility (%) | 23 | 55.65 ± 6.44 | 16 | 55.56 ± 6.81 | 0.976 |
| Rapid Progressive Motility (%) | 23 | 1.13 ± 2.99 | 16 | 3.63 ± 7.21 | 0.113 |
| Slow Progressive Motility (%) | 23 | 45.91 ± 9.01 | 16 | 39.94 ± 9.81 | 0.043 |
| Non-progressive Motility (%) | 23 | 34.70 ± 7.25 | 16 | 29.75 ± 11.59 | 0.244 |
| Immotility (%) | 23 | 18.26 ± 7.62 | 16 | 26.31 ± 13.45 | 0.053 |
| Typical Morphology (%) | 23 | 9.26 ± 2.94 | 16 | 7.19 ± 2.83 | 0.020 |
| Head Abnormalities (%) | 0 | 1 | 94.00± | ||
| Midpiece Abnormalities (%) | 0 | 1 | 18.00± | ||
| Tail Abnormalities (%) | 0 | 1 | 10.00± | ||
| Immature Forms (%) | 0 | 1 | 0.000± | ||
| sORP (mV/106 sperm/mL) | 3 | 0.690 ± 0.345 | 6 | 1.023 ± 0.959 | 0.796 |
| Viscosity (cps) | |||||
| normal | 3 (13.0%) | 2 (12.5%) | |||
| abnormal | 20 (87.0%) | 14 (87.5%) | 0.960 | ||
| Liquefaction | |||||
| normal | 2 (8.7%) | 1 (6.2%) | |||
| abnormal | 21 (91.3%) | 15 (93.8%) | 0.778 |
Values are mean ± SD or number (column percentage). Mann–Whitney U test or Chi-square test was used.
Table 4.
Association of GSTM1-null genotype with conventional semen parameters (study group).
| Semen Parameters | N0 | GSTM1 (No) | N1 | GSTM1 (Yes) | p-Value |
|---|---|---|---|---|---|
| pH | 19 | 7.621 ± 0.190 | 26 | 7.623 ± 0.234 | 0.972 |
| Days of Abstinence | 20 | 3.750 ± 2.770 | 31 | 3.968 ± 1.779 | 0.268 |
| Semen Volume (mL) | 20 | 2.580 ± 1.240 | 31 | 3.381 ± 1.992 | 0.202 |
| Sperm Concentration (106/mL) | 20 | 24.96 ± 25.36 | 31 | 27.95 ± 31.54 | 0.847 |
| Total Sperm Count (106) | 20 | 57.87 ± 59.78 | 31 | 96.72 ± 119.35 | 0.657 |
| Total Motility (%) | 20 | 47.75 ± 11.26 | 31 | 47.84 ± 13.04 | 0.787 |
| Rapid Progressive Motility (%) | 20 | 6.50 ± 7.26 | 31 | 7.90 ± 10.16 | 0.627 |
| Slow Progressive Motility (%) | 20 | 20.40 ± 7.05 | 31 | 20.90 ± 8.93 | 0.764 |
| Non-progressive Motility (%) | 20 | 21.85 ± 11.73 | 31 | 23.55 ± 15.80 | 0.802 |
| Immotility (%) | 20 | 51.25 ± 12.31 | 31 | 47.32 ± 16.01 | 0.429 |
| Typical Morphology (%) | 20 | 2.20 ± 1.11 | 31 | 3.23 ± 2.80 | 0.456 |
| Head Abnormalities (%) | 9 | 98.222 ± 0.833 | 12 | 98.750 ± 0.622 | 0.081 |
| Midpiece Abnormalities (%) | 9 | 26.444 ± 6.126 | 12 | 30.083 ± 8.785 | 0.200 |
| Tail Abnormalities (%) | 9 | 15.222 ± 11.032 | 12 | 14.083 ± 9.337 | 0.475 |
| Immature Forms (%) | 9 | 6.667 ± 2.828 | 12 | 6.667 ± 3.701 | 0.721 |
| sORP (mV/106 sperm/mL) | 17 | 6.140 ± 11.481 | 26 | 4.827 ± 5.521 | 0.737 |
| Viscosity (cps) | |||||
| normal | 5 (25.0%) | 7 (22.6%) | |||
| abnormal | 15 (75.0%) | 24 (77.4%) | 0.842 | ||
| Liquefaction | |||||
| normal | 0 (0.0%) | 2 (6.5%) | |||
| abnormal | 20 (100%) | 29 (93.5%) | 0.247 |
Values are mean ± SD or number (column percentage). Mann–Whitney U test or Chi-square test was used.
Table 5.
Association of Static Oxidation-reduction Potential (sORP) with conventional semen parameters (study group).
Table 5.
Association of Static Oxidation-reduction Potential (sORP) with conventional semen parameters (study group).
| Semen Parameters | N | Pearson’s Correlation | p-Value |
|---|---|---|---|
| pH | 43 | −0.190 | 0.222 |
| Days of Abstinence | 43 | −0.060 | 0.703 |
| Semen Volume (mL) | 43 | 0.226 | 0.145 |
| Sperm Concentration (106/mL) | 43 | −0.369 | 0.015 |
| Total Sperm Count (106) | 43 | −0.315 | 0.040 |
| Total Motility (%) | 43 | −0.278 | 0.071 |
| Rapid Progressive Motility (%) | 43 | −0.280 | 0.069 |
| Slow Progressive Motility (%) | 43 | −0.348 | 0.022 |
| Non-progressive Motility (%) | 43 | 0.277 | 0.072 |
| Immotility (%) | 43 | 0.275 | 0.075 |
| Typical Morphology (%) | 43 | −0.051 | 0.743 |
| Head Abnormalities (%) | 21 | 0.189 | 0.411 |
| Midpiece Abnormalities (%) | 21 | −0.059 | 0.801 |
| Tail Abnormalities (%) | 21 | 0.006 | 0.980 |
| Immature Forms (%) | 21 | 0.421 | 0.057 |
Pearson correlation was used.
Table 6.
Association of Static Oxidation-reduction Potential (sORP) with conventional semen parameters (control group).
Table 6.
Association of Static Oxidation-reduction Potential (sORP) with conventional semen parameters (control group).
| Semen Parameters | N | Pearson’s Correlation | p-Value |
|---|---|---|---|
| pH | 9 | 0.259 | 0.500 |
| Days of Abstinence | 9 | −0.044 | 0.910 |
| Semen Volume (mL) | 9 | 0.274 | 0.476 |
| Sperm Concentration (106/mL) | 9 | −0.375 | 0.320 |
| Total Sperm Count (106) | 9 | −0.074 | 0.851 |
| Total Motility (%) | 9 | −0.701 | 0.035 |
| Rapid Progressive Motility (%) | 9 | −0.021 | 0.957 |
| Slow Progressive Motility (%) | 9 | −0.473 | 0.198 |
| Non-Progressive Motility (%) | 9 | −0.554 | 0.122 |
| Immotility (%) | 9 | 0.701 | 0.035 |
| Typical Morphology (%) | 9 | 0.028 | 0.943 |
| Head Abnormalities (%) | 1 | ||
| Midpiece Abnormalities (%) | 1 | ||
| Tail Abnormalities (%) | 1 | ||
| Immature Forms (%) | 1 |
Pearson correlation was used.
Table 7.
Association of Static Oxidation-reduction Potential (sORP) with Viscosity and Liquefaction in both groups.
Table 7.
Association of Static Oxidation-reduction Potential (sORP) with Viscosity and Liquefaction in both groups.
| Control Group | |||||
| N1 | Normal | N2 | Abnormal | p-Value | |
| Viscosity (cps) | 2 | 1.925 ± 1.266 | 7 | 0.623 ± 0.370 | 0.079 |
| Liquefaction | 0 | 9 | 0.912 ± 0.795 | ||
| Study Group | |||||
| N1 | Normal | N2 | Abnormal | p-Value | |
| Viscosity (cps) | 9 | 11.767 ± 15.09 | 34 | 3.645 ± 4.252 | 0.022 |
| Liquefaction | 0 | 43 | 5.345 ± 8.293 | ||
Mann–Whitney U test was used.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Potiris, A.; Voitse, A.; Mavrogianni, D.; Machairiotis, N.; Drakaki, E.; Papamentzelopoulou, M.; Karampitsakos, T.; Zikopoulos, A.; Evgeni, E.; Drakakis, P.; et al. Association of GSTM1 Polymorphism and Redox Potential with Idiopathic Male Infertility. J. Clin. Med. 2023, 12, 6775. https://doi.org/10.3390/jcm12216775
AMA Style
Potiris A, Voitse A, Mavrogianni D, Machairiotis N, Drakaki E, Papamentzelopoulou M, Karampitsakos T, Zikopoulos A, Evgeni E, Drakakis P, et al. Association of GSTM1 Polymorphism and Redox Potential with Idiopathic Male Infertility. Journal of Clinical Medicine. 2023; 12(21):6775. https://doi.org/10.3390/jcm12216775
Chicago/Turabian StylePotiris, Anastasios, Anastasia Voitse, Despoina Mavrogianni, Nikolaos Machairiotis, Eirini Drakaki, Myrto Papamentzelopoulou, Theodoros Karampitsakos, Athanasios Zikopoulos, Evangelini Evgeni, Peter Drakakis, and et al. 2023. "Association of GSTM1 Polymorphism and Redox Potential with Idiopathic Male Infertility" Journal of Clinical Medicine 12, no. 21: 6775. https://doi.org/10.3390/jcm12216775
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
